Stockreport

Regeneron Eyes Longer EYLEA HD Dosing As Valuation Gap Persists [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
PDF Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular ede [Read more]